MIG Fonds et al. invest €5.5m in Isarna Therapeutics

MIG Fonds has been the most significant investor in Isarna to date, first investing in 2005. Bayern Kapital previously invested in the biotech in 2008.

The company will use the fresh capital to develop TGF beta inhibitors, which are designed to stimulate the human immune system to fight cancer and other diseases.

Company
Founded in 1998 as Antisense Pharma, Isarna aims to use TGF beta therapeutics in cancer immunotherapy and in treating ocular diseases and fibrosis. The company is headquartered in Munich and has recently opened a new office in New York. It employs 18 staff.

People
Philippe Calais is CEO at Isarna.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Healthcare
• Early-stage
• Germany